Glucocorticoids in the management of systemic juvenile idiopathic arthritis

Pediatric Drugs

Volumn 15, Issue 5, 2013, Pages 343-349

  Vannucci, Gaia ^a   Cantarini, Luca ^b   Giani, Teresa ^a   Marrani, Edoardo ^a   Moretti, Davide ^a   Pagnini, Ilaria ^a   Simonini, Gabriele ^a   Cimaz, Rolando ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885663847     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0038-0     Document Type: Article

References (48)

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J Rheumatol. 2004;31(2):390-2.
2. De Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Cassidy J, Petty R, Laxer RM, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 236-48.
3. Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343-8.
4. Bywaters EG, Isdale IC. The rash of rheumatoid arthritis and Still's disease. Q J Med. 1956;25(99):377-87.
5. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Bailliere Clin Rheum. 1998;2:245-71.
6. Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam. 2012;. doi: 10.1155/2012/271569.
7. Cimaz R, Von Scheven A, Hofer M. Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease. Swiss Med Wkly. 2012;142:w13582.
8. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28-34.
9. Schaller JG. Juvenile rheumatoid arthritis: series 1. Arthritis Rheum. 1977;20(2):165-70.
10. Stoeber E. Prognosis in juvenile chronic arthritis: follow-up of 433 chronic rheumatic children. Eur J Pediatr. 1981;135(3):225-8.
11. Ansell BM. Prognosis in juvenile arthritis. Adv Exp Med Biol. 1999;455:27-33.
12. Laxer RM, Schneider R. Systemic-onset juvenile chronic arthritis. In: Isenberg DA, et al., editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 2004. p. 798-810.
13. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747-54.
14. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-406.
15. Lovell DJ, Giannini E, Kimura Y, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum. 2009;. doi: 10.1002/art.27125.
16. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-95.
17. Bader-Meunier B, Wouters C, Job-Deslandrec C, et al. Recommandations pour la prise en charge de la forme systemique l'arthrite juvenile idiopathique (maladie de Still). Arch Pediatr. 2010;17(7):1090-4.
18. Spahn JD, Kamada AK. Special considerations in the use of glucocorticoids in children. Pediatr Rev. 1995;16(7):266-72.
19. Chan LF, Storr HL, Grossman AB, et al. Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. Arq Bras Endocrinol Metabol. 2007;51(8):1261-71.
20. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol. 2013;. doi: 10.1038/nrendo.2013.5.
21. Dieguez C, Mallo F, Señaris R, et al. Role of glucocorticoids in the neuroregulation of growth hormone secretion. J Pediatr Endocrinol Metab. 1996;9(3):255-60.
22. Simon D, Fernando C, Czernichow P, et al. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol. 2002;29(6):1296-300.
23. Savage MO, Simon D, Czernichow PC. Growth hormone treatment in children on chronic glucorticoid therapy. Endocr Dev. 2011;20:194-201.
24. Mauras N. Strategies for maximizing growth in puberty in children with short stature. Pediatr Clin North Am. 2011;58(5):1167-79.
25. Burnham JM. Inflammatory diseases and bone health in children. Curr Opin Rheumatol. 2012;24(5):548-53.
26. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int. 1987;41(2):75-8.
27. Valta H, Lahdenne P, Jalanko H, et al. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34(4):831-6.
28. Bishop N, Braillon P, Burnham J, et al. Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD pediatric official positions. J Clin Densitom. 2008;11(1):29-42.
29. Ma NS, Gordon CM. Pediatric osteoporosis: where are we now? J Pediatr. 2012;161(6):983-90.
30. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491-6.
31. Ravelli A, Lattanzi B, Consolaro A, et al. Glucocorticoids in paediatric rheumatology. Clin Exp Rheumatol. 2011;29(5):148-52.
32. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. J Rheumatol. 1998;37(11):1240-2.
33. Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C. 6-Methylprednisolone "mini-pulses": a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheum. 1996;25(1):24-7.
34. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol. 1998;25(10):1995-2002.
35. Kimura Y, Fieldston E, Devries-Vandervlugt B, et al. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2000;27(8):2018-24.
36. Clarke L, Kirwan J. Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Adv Musculoskelet Dis. 2012;4(3):159-66.
37. Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol. 2013;53(3):326-33.
38. Ilowite NT, Laxer RM. Pharmacology and drug therapy. In: Cassidy J, Petty R, Laxer RM, et al., editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 71-126.
39. Job-Delsandre C, Menkes CJ. Complications of intraarticular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol. 1990;8(4):413-6.
40. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465-82.
41. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-9.
42. Dewitt ES, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64(7):1001-10.
43. Ilowite NT, Sandborg CI, Feldman BM, et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J. 2012;10(1):31.
44. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421-6.
45. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655-64.
46. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;. doi: 10.1016/j.jpeds.2012.11.081.
47. Ravelli A, Viola S, De Benedetti F, et al. Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clin Exp Rheumatol. 2001;19(1):108.
48. Egeler RM, Webb D, Winiarski J, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31.